Merck & Co Inc (MRK):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Merck & Co Inc (MRK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10059)・商品コード:DATA904C10059
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:458
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Merck & Co Inc (Merck) is a biopharmaceutical company that focuses on the discovery, development, manufacture and commercialization of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products including vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. Outside the US, the company operates through subsidiaries. It operates in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc (MRK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 11
List of Figures 16
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17
Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20
Merck & Co Inc, Medical Devices Deals, 2012 to YTD 2018 22
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23
Merck & Co Inc, Pharmaceuticals & Healthcare, Deal Details 38
Asset Purchase 38
Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 38
Venture Financing 39
Moderna Therapeutics Raises USD125 Million in Series H Preferred Equity Financing 39
Rigontec Raises Additional USD16.7 Million in Series A Financing 40
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 42
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 44
RaNA Therapeutics Raises USD55 Million in series B Financing 45
Afferent Pharma Raises USD55 Million in Series C Financing 46
Gladius Pharma Raises USD3.3 Million in Series A Financing 47
Rigontec Raises Additional USD5.21 Million in Series A Financing 48
NGM Biopharma Raises USD106 Million in Series E Financing 49
EnGene Raises USD11 Million in Series B Venture Financing 50
OsteoQC Raises Funds through Seed Financing 51
Rigontec Raises USD12 Million in Series A Venture Financing 52
ImaginAb Raises USD21 Million in Series B Venture Financing 53
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 54
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 55
OncoEthix Raises US$19 Million In Series B Financing 56
Aviir Raises US$20 Million In Venture Financing 58
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding Round 60
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 61
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding 62
Partnerships 63
Antigen Express Enters into Agreement with Merck for KEYTRUDA 63
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 64
FLX Bio Enters into Agreement with Merck 65
Eisai and MSD Enter into Co-Marketing Agreement 66
eFFECTOR Therapeutics Enters into Agreement with Merck 67
Dragonfly Therapeutics Enters into Collaboration Agreement with Merck 68
Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 69
IMV Enters into Partnership with Merck 70
IRBM Science Park Enters into Collaboration Agreement with Merck 71
University of Western Australia and Merck Enter into Research Partnership 72
Rexahn Pharma Enters into Clinical Trial Collaboration Agreement with Merck 73
4D pharma Enters into Agreement with Merck 74
MSD Enters into Distribution Agreement with Kyorin Pharma 75
OncoSec Medical Enters into Agreement with Merck 76
IO Biotech Enters into Clinical Trial Collaboration Agreement with Merck 77
Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck 78
Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 79
Merck to Enter into Agreement with Schneider Electric 80
PharmAbcine Enters into Agreement with Merck 81
Parkinson’s Institute and Clinical Center Enters into Agreement with Merck 82
Grunenthal Enters into Distribution Agreement with Merck 83
Astellas Pharma Enters into Co-Promotion Agreement with MSD 84
Aeglea BioTherapeutics Enters into Agreement with Merck 85
KalVista Pharma Enters into Agreement with Merck 86
SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 87
Eisai Enters into Agreement with Merck for Eribulin 88
Eisai Enters into Agreement with Merck 89
AstraZeneca Enters into Agreement with Merck 90
Invenra Enters into Agreement With Merck 91
PDS Biotech Enters into Agreement with Merck 92
Leap Therapeutics Enters into Agreement with Merck International 93
Aduro Biotech Expands Agreement with Merck 94
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 95
Array BioPharma Enters into Agreement with Merck 96
Atara Biotherapeutics Enters into Agreement with Merck 97
HitGen Expands Agreement with Merck 98
BerGenBio Enters into Agreement with Merck 99
Stratophase Enters into Agreement with Merck 100
CMIC Enters into Agreement with MSD for Diazoxide 101
Ramot at Tel Aviv University Enters into Research Agreement with Merck 102
NOXXON Pharma Enters into Agreement with Merck 103
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 104
Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 105
Genexine Enters into Clinical Research Agreement with Merck 106
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 107
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 108
Merck Enters into Distribution Agreement with JenKem Tech 109
MSD Enters into Agreement with Kyorin Pharma 110
Agency for Science, Technology and Research Enters into Agreement with Merck 111
Menarini Asia-Pacific Enters into Agreement with Merck 112
Innovative Targeting Solutions Enters into Research Agreement with Merck 113
Fujifilm Diosynth Biotech Partners with Merck 114
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 115
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 116
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 117
ImmunoGen Enters into Research Agreement with Merck 118
Merck Enters into Agreement with AbCellera Biologics 119
Affimed Enters into Research Agreement with Merck 120
BioLineRx Expands Licensing Agreement with Merck 121
Quartet Medicine Enters into Agreement with Merck 122
Complix Expands Agreement with Merck 123
Eli Lilly Expands its Agreement with Merck 124
Merck Enters into Agreement with Akeso Biopharma 125
Amgen and Merck Enter into Agreement 126
Viralytics Enters into Agreement with Merck 127
GlaxoSmithKline Partners with Merck 128
Synthace Enters into Agreement with Merck 129
MacroGenics Enters into Agreement with Merck 130
Incyte Extends Partnership with Merck 131
Proteros Enters Into an Agreement with Merck Sharp and Dohme 132
Merck Enters into Agreement with OBI Pharma 133
Merck Enters into Agreement with DNAtrix 134
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 135
Immune Design Enters into Clinical Collaboration Agreement with Merck 136
Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 137
Plexxikon Enters into Agreement with Merck 138
PeptiDream Enters into Peptide Discovery Agreement with Merck 139
Organovo Enters into Research Agreement with Merck Sharp & Dohme 140
Syndax Pharma Expands its Agreement with Merck 141
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 142
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 143
Merck Expands Agreement with Eli Lilly 144
Enumeral Biomedical Amends Agreement with Merck Sharp & Dohme 145
Kyorin Pharma Amends Co-Marketing Agreement with MSD 146
Bind Therapeutics Enters into R&D Agreement with Merck 147
Advaxis Enters into Agreement with Merck 148
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 149
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 150
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 151
Dako Enters Into Co-Development Agreement With Merck 152
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 153
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 154
Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 156
Abide Therapeutics Enters Into Co-Development Agreement With Merck 157
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 158
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 159
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 160
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 161
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 162
ActoGeniX Enters Into Research Agreement With Merck 163
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 164
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 165
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 166
Redbiotec Extends Drug Discovery Agreement With Merck 168
Merck Forms Joint Venture With Supera Farma Laboratorios 169
MSD Enters Into Distribution Agreement With Julphar 170
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 171
Fundacion Medina Enters Into Research Agreement With Cubist Pharma 172
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 173
MSD India Plans Co-Marketing Agreement For Diabetes Drugs 174
Licensing Agreements 175
Perrigo Enters into Licensing Agreement with Merck 175
Merck Enters into Licensing Agreement with Sutro Biopharma 176
Prokaryotics Enters into Licensing Agreement with Merck 177
Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 178
Merck Enters into Licensing Agreement with Cue Biopharma 179
Dongwha Pharm Enters into Licensing Agreement with Merck 180
Merck Enters into Licensing And Option Agreement with AIMM Therapeutics 181
Merck Enters into Licensing Agreement with Teijin Pharma 182
Kyorin Pharma Enters into Licensing Agreement with Merck 183
Urovant Sciences Enters into Licensing Agreement with Merck Sharp & Dohme 184
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 185
Ascentage Pharma Enters into Licensing Agreement with Merck 186
Merck Expands Licensing Agreement with Moderna Therapeutics 187
Merck Enters into Licensing Agreement with Harvard University 189
Merck Enters into Licensing Agreement with AureoGen Biosciences 190
Merck Enters into Licensing Agreement with Cancer Research Technology 191
Adimab Enters into Licensing Agreement with Merck 192
Merck Enters into Licensing Agreement with Selvita 193
Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 194
Allergan Enters into Licensing Agreement with Merck 196
Merck Extends Licensing Agreement with Agenus 197
Arvinas Enters into Licensing Agreement with Merck 198
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 199
Merck Enters into Licensing Agreement with BioNovion 200
Zymeworks Extends Licensing Agreement with Merck 201
Merck Enters into Licensing Agreement with NewLink Genetics 202
Euroscreen Enters into Licensing Agreement with Merck 204
Sun Pharma Enters into Licensing Agreement with Merck 205
Kyorin Pharma Enters into Licensing Agreement with Merck 206
Bionomics Enters into Licensing Agreement with Merck for BNC375 207
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 208
Gulf Pharma Enters into Licensing Agreement with MSD 209
Gulf Pharmaceutical Industries (Julphar) Enters into Licensing Agreement with Merck 210
NanoBio Enters Into Licensing Agreement With Merck 211
Merck Expands Licensing Agreement with Ablynx 212
ARMO Biosciences Enters into Licensing Agreement with Merck 214
Bionomics Extends Licensing Agreement with Merck 215
Xencor Enters Into Licensing Agreement With Merck 216
Cerecor Enters Into Licensing Agreement With Merck For MK-0657 217
Meiji Seika Pharma Enters into Licensing Agreement with MSD 218
Merck Enters into Licensing Agreement with Ra Pharma 219
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 221
Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 222
Menlo Therapeutics Enters into Licensing Agreement with Merck 223
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 224
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 225
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 226
MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 227
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 228
Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 229
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 230
Merck Enters into Licensing Agreement with Medicines Patent Pool 231
EnWave Enters into Licensing Agreement with Merck 232
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 233
Polyplus-transfection Enters Into Licensing Agreement With Merck 235
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 236
Merck Enters Into Licensing Agreement With Lupin 238
Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 239
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 240
Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 241
Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 242
Merck Enters Into Licensing Agreement With Yamasa For EFdA 243
Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 244
Merck Extends Licensing Agreement with Codexis 245
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 246
Equity Offering 247
Bionomics Raises USD9 Million in Private Placement of Shares 247
OpGen Raises USD5 Million in Private Placement of Shares 248
BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 249
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 250
BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 251
Trius Therapeutics Completes Public Offering Of Shares For US$34 Million 252
Trius Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$5 Million 253
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 255
Trius Therapeutics Completes Over-allotment Option Of Underwritten Public Offering For US$52 Million 256
Debt Offering 258
Merck Plans to Raise Funds through Public Offering of Debt Securities 258
Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 259
Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 260
Merck Completes Public Offering of Notes Due 2020 for USD700 Million 261
Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 263
Merck Completes Public Offering of Notes Due 2017 for USD300 Million 265
Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 267
Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 269
Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 271
Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 273
Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 275
Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 277
Cubist Pharma Completes Private Placement Of Notes Due 2020 For US$450 Million 279
Cubist Pharma Completes Private Placement Of Notes Due 2018 For US$350 Million 280
Merck Completes Public Offering Of Notes Due 2016 For US$500 Million 281
Merck Completes Public Offering Of Notes Due 2016 For US$1 Billion 283
Merck Completes Public Offering Of Notes Due 2018 For US$1 Billion 285
Merck Completes Public Offering Of Notes Due 2023 For US$1.75 Billion 287
Merck Completes Public Offering Of Notes Due 2043 For US$1.25 Billion 289
Merck Completes Public Offering Of Floating Notes Due 2018 For US$1 Billion 291
BeiGene Raises USD3 Million in Private Placement of Notes 293
Merck Completes Public Offering Of Notes Due 2042 For US$500 Million 294
Merck Completes Public Offering Of 1.1% Notes Due 2018 For US$1 Billion 296
Merck Completes Public Offering Of Notes Due 2022 For US$1 Billion 298
Asset Transactions 300
Pharmaron Acquires Hoddesdon UK Site from Merck Sharpe & Dohme 300
Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 301
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 303
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 304
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 305
Fareva Acquires La Vallee Manufacturing Site from Merck 306
Merial Acquires Manufacturing Facility from Merck 307
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 308
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 310
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 312
KBI Biopharma To Acquire Biologics Operations Of Merck 314
Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 315
Oak Pharma Acquires Tafluprost Business from Merck 316
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 317
Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme 318
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 319
Cerecor Acquires Rights To COMT Inhibitors From Merck 320
Kyorin Acquires Production Facility from MSD 322
Acquisition 323
Merck Acquires Viralytics for USD394 Million 323
Merck Acquires Rigontec 325
Paratek Pharma May Sell Itself 327
Merck Acquires Afferent Pharma 329
Merck Acquires IOmet Pharma 330
Merck Acquires cCAM Biotherapeutics 331
Merck Acquires Cubist Pharma for USD9.5 Billion 332
Merck Acquires OncoEthix for USD375 Million 334
Merck Completes Acquisition of Idenix Pharma for USD3.9 Billion in cash 335
Alnylam Pharma Acquires Sirna Therapeutics From Merck 337
Akorn Acquires Inspire Pharma From Merck For US$53 Million 338
Cubist Pharma Completes Acquisition of Optimer Pharma for up to USD801 Million 340
Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To US$818 Million In A Tender Offer 342
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 344
Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 346
Merck & Co Inc – Key Competitors 347
Merck & Co Inc – Key Employees 348
Merck & Co Inc – Locations And Subsidiaries 350
Head Office 350
Other Locations & Subsidiaries 350
Joint Venture 372
Recent Developments 374
Strategy And Business Planning 374
Oct 04, 2018: Merck Opens M Lab Collaboration Center in Sao Paulo, Brazil 374
Oct 03, 2018: Merck and Dragonfly partner to develop cancer immunotherapies 375
Nov 27, 2017: MSD announces plan to establish UK Discovery Centre in London 376
Jul 17, 2017: Governor Abbott Announces Merck IT Hub In Austin 377
Mar 02, 2017: Allergopharma Opens new Biopharmaceutical Production in Reinbek 378
Financial Announcements 379
Oct 25, 2018: Merck announces third-quarter 2018 financial results 379
Jul 27, 2018: Merck Announces Second-Quarter 2018 Financial Results 383
May 01, 2018: Merck Announces First-Quarter 2018 Financial Results 387
Oct 27, 2017: Merck Announces Third-Quarter 2017 Financial Results 390
Jul 28, 2017: Merck Announces Second-Quarter 2017 Financial Results 392
May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 395
Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 397
Corporate Communications 399
Oct 17, 2018: Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer 399
Jan 24, 2018: Merck Names Inge Thulin To Board Of Directors 400
Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 401
Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 402
Legal and Regulatory 403
Apr 25, 2018: Fish & Richardson Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead After Merck’s “Unclean Hands” 403
Feb 19, 2018: Gilead wins reversal in $2.5 billion dispute with Merck 404
Feb 15, 2017: Merck’s Wholly Owned Subsidiary Idenix Pharmaceuticals Awarded $2.54 Billion for Infringement of a Hepatitis C Drug Patent 405
Government and Public Interest 406
Oct 16, 2018: Merck Aims to Return to Profitable Growth as of 2019 406
Aug 02, 2018: New method of molecular coupling offers potential to expedite drug discovery process 407
Jul 17, 2018: Merck Announces Future Insight Prize of up to € 1 Million for Groundbreaking Scientific Work 410
Dec 05, 2017: Bioethics International Releases the “Good Pharma Scorecard” in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 411
Oct 19, 2017: Merck Foundation Launches Five-Year Initiative to Improve Diabetes Care for Vulnerable and Underserved U.S. Communities 412
Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 413
Feb 09, 2017: Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care 414
Jan 19, 2017: MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers 415
Jan 18, 2017: Merck Foundation Grant Expands Project ECHO in Vietnam and India 416
Product News 417
11/21/2017: Medicure Reports Financial Results for Quarter Ended September 30, 2017 417
Oct 29, 2018: Samsung Bioepis riding the biosimilar third wave 419
10/12/2017: Merck Sharp & Dohme receives CHMP positive opinion for Cubicin 420
10/02/2017: Study Published in Nature Reveals Molecular Pathway of Weight-Controlling Hormone, Enabling the Discovery of Multiple Drug Candidates, Including NGM386 for Obesity 421
08/15/2018: Agenus receives second milestone payment from Merck 422
07/17/2017: Cardiome Announces Health Canada Approval of AGGRASTAT High Dose Bolus Regimen 423
07/13/2017: Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer 424
07/02/2018: Astellas Received Approval for Dafclir Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan 425
05/03/2017: Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer 426
04/24/2018: Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria 427
04/19/2017: Merck to Present Data on Relebactam at ECCMID 2017 428
04/02/2018: Eiger BioPharmaceuticals to Participate in Conferences in April 429
02/16/2017: Antibiotic effective against drug-resistant bacteria in pediatric skin infections 430
Product Approvals 431
Feb 12, 2018: Merck’s Cubicin Rejects For Use Within NHS Scotland 431
Jan 23, 2018: Cardiome Announces Expanded Label for Aggrastat in China Including New STEMI Indication and High Dose Bolus Regimen 432
Jul 31, 2017: Astellas Submits Application for Approval of fidaxomicin for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan 433
Clinical Trials 434
Jun 04, 2018: Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018 434
Apr 24, 2018: Merck pits its pneumococcal shot against Pfizer mammoth Prevnar in head-to-head phase 3 435
Apr 17, 2018: Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress 2018 436
Apr 17, 2018: Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine 437
Mar 21, 2018: Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program 438
Mar 05, 2018: Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors 439
Mar 05, 2018: Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting 440
Oct 23, 2017: Eiger Presents Data on Lonafarnib at the American Association for the Study of Liver Diseases Meeting 441
Oct 02, 2017: Eiger Announces Presentation on Lonafarnib at the American Association for the Study of Liver Diseases Meeting 442
Jul 06, 2017: Merck to Present Data from on MK-8591 at IAS 2017 443
Apr 21, 2017: Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017 444
Apr 06, 2017: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting 446
Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer’s Treatment 447
Other Significant Developments 448
Nov 05, 2018: Merck launches Biocontinuum platform for next-generation process improvements 448
Oct 08, 2018: Merck’s novel Chemiflex raw materials program solves regulatory compliance challenges in small molecule drug manufacturing 449
Oct 01, 2018: Merck announces “Safer Childbirth Cities” initiative, issues call to action to reverse the rise in U.S. maternal deaths 450
Sep 20, 2018: Merck publishes Corporate Responsibility Report 451
Jul 19, 2018: HHS Secretary Azar Praises Merck’s Decision to Cut Drug Prices 452
Nov 13, 2017: PeptiDream Announces 2 nd Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck & Co., Inc., Kenilworth, N.J., U.S.A 453
Oct 09, 2017: Johnson & Johnson investing $350M in EU biologics operation, adding 200 jobs 454
Jun 22, 2017: Merck and Premier Expand Collaboration to Address Chronic Care and Vaccination Rates 455
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck 456
Feb 16, 2017: Merck’s Fight Against Infectious Disease Goes Digital with Launch of ILUM Health Solutions 457
Appendix 458
Methodology 458
About GlobalData 458
Contact Us 458
Disclaimer 458

List of Tables
Merck & Co Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17
Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19
Merck & Co Inc, Deals By Therapy Area, 2012 to YTD 2018 20
Merck & Co Inc, Medical Devices Deals, 2012 to YTD 2018 22
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23
Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 38
Moderna Therapeutics Raises USD125 Million in Series H Preferred Equity Financing 39
Rigontec Raises Additional USD16.7 Million in Series A Financing 40
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 42
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 44
RaNA Therapeutics Raises USD55 Million in series B Financing 45
Afferent Pharma Raises USD55 Million in Series C Financing 46
Gladius Pharma Raises USD3.3 Million in Series A Financing 47
Rigontec Raises Additional USD5.21 Million in Series A Financing 48
NGM Biopharma Raises USD106 Million in Series E Financing 49
EnGene Raises USD11 Million in Series B Venture Financing 50
OsteoQC Raises Funds through Seed Financing 51
Rigontec Raises USD12 Million in Series A Venture Financing 52
ImaginAb Raises USD21 Million in Series B Venture Financing 53
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 54
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 55
OncoEthix Raises US$19 Million In Series B Financing 56
Aviir Raises US$20 Million In Venture Financing 58
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding Round 60
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 61
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding 62
Antigen Express Enters into Agreement with Merck for KEYTRUDA 63
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 64
FLX Bio Enters into Agreement with Merck 65
Eisai and MSD Enter into Co-Marketing Agreement 66
eFFECTOR Therapeutics Enters into Agreement with Merck 67
Dragonfly Therapeutics Enters into Collaboration Agreement with Merck 68
Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 69
IMV Enters into Partnership with Merck 70
IRBM Science Park Enters into Collaboration Agreement with Merck 71
University of Western Australia and Merck Enter into Research Partnership 72
Rexahn Pharma Enters into Clinical Trial Collaboration Agreement with Merck 73
4D pharma Enters into Agreement with Merck 74
MSD Enters into Distribution Agreement with Kyorin Pharma 75
OncoSec Medical Enters into Agreement with Merck 76
IO Biotech Enters into Clinical Trial Collaboration Agreement with Merck 77
Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck 78
Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 79
Merck to Enter into Agreement with Schneider Electric 80
PharmAbcine Enters into Agreement with Merck 81
Parkinson’s Institute and Clinical Center Enters into Agreement with Merck 82
Grunenthal Enters into Distribution Agreement with Merck 83
Astellas Pharma Enters into Co-Promotion Agreement with MSD 84
Aeglea BioTherapeutics Enters into Agreement with Merck 85
KalVista Pharma Enters into Agreement with Merck 86
SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 87
Eisai Enters into Agreement with Merck for Eribulin 88
Eisai Enters into Agreement with Merck 89
AstraZeneca Enters into Agreement with Merck 90
Invenra Enters into Agreement With Merck 91
PDS Biotech Enters into Agreement with Merck 92
Leap Therapeutics Enters into Agreement with Merck International 93
Aduro Biotech Expands Agreement with Merck 94
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 95
Array BioPharma Enters into Agreement with Merck 96
Atara Biotherapeutics Enters into Agreement with Merck 97
HitGen Expands Agreement with Merck 98
BerGenBio Enters into Agreement with Merck 99
Stratophase Enters into Agreement with Merck 100
CMIC Enters into Agreement with MSD for Diazoxide 101
Ramot at Tel Aviv University Enters into Research Agreement with Merck 102
NOXXON Pharma Enters into Agreement with Merck 103
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 104
Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 105
Genexine Enters into Clinical Research Agreement with Merck 106
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 107
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 108
Merck Enters into Distribution Agreement with JenKem Tech 109
MSD Enters into Agreement with Kyorin Pharma 110
Agency for Science, Technology and Research Enters into Agreement with Merck 111
Menarini Asia-Pacific Enters into Agreement with Merck 112
Innovative Targeting Solutions Enters into Research Agreement with Merck 113
Fujifilm Diosynth Biotech Partners with Merck 114
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 115
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 116
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 117
ImmunoGen Enters into Research Agreement with Merck 118
Merck Enters into Agreement with AbCellera Biologics 119
Affimed Enters into Research Agreement with Merck 120
BioLineRx Expands Licensing Agreement with Merck 121
Quartet Medicine Enters into Agreement with Merck 122
Complix Expands Agreement with Merck 123
Eli Lilly Expands its Agreement with Merck 124
Merck Enters into Agreement with Akeso Biopharma 125
Amgen and Merck Enter into Agreement 126
Viralytics Enters into Agreement with Merck 127
GlaxoSmithKline Partners with Merck 128
Synthace Enters into Agreement with Merck 129
MacroGenics Enters into Agreement with Merck 130
Incyte Extends Partnership with Merck 131
Proteros Enters Into an Agreement with Merck Sharp and Dohme 132
Merck Enters into Agreement with OBI Pharma 133
Merck Enters into Agreement with DNAtrix 134
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 135
Immune Design Enters into Clinical Collaboration Agreement with Merck 136
Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 137
Plexxikon Enters into Agreement with Merck 138
PeptiDream Enters into Peptide Discovery Agreement with Merck 139
Organovo Enters into Research Agreement with Merck Sharp & Dohme 140
Syndax Pharma Expands its Agreement with Merck 141
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 142
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 143
Merck Expands Agreement with Eli Lilly 144
Enumeral Biomedical Amends Agreement with Merck Sharp & Dohme 145
Kyorin Pharma Amends Co-Marketing Agreement with MSD 146
Bind Therapeutics Enters into R&D Agreement with Merck 147
Advaxis Enters into Agreement with Merck 148
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 149
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 150
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 151
Dako Enters Into Co-Development Agreement With Merck 152
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 153
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 154
Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 156
Abide Therapeutics Enters Into Co-Development Agreement With Merck 157
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 158
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 159
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 160
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 161
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 162
ActoGeniX Enters Into Research Agreement With Merck 163
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 164
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 165
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 166
Redbiotec Extends Drug Discovery Agreement With Merck 168
Merck Forms Joint Venture With Supera Farma Laboratorios 169
MSD Enters Into Distribution Agreement With Julphar 170
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 171
Fundacion Medina Enters Into Research Agreement With Cubist Pharma 172
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 173
MSD India Plans Co-Marketing Agreement For Diabetes Drugs 174
Perrigo Enters into Licensing Agreement with Merck 175
Merck Enters into Licensing Agreement with Sutro Biopharma 176
Prokaryotics Enters into Licensing Agreement with Merck 177
Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 178
Merck Enters into Licensing Agreement with Cue Biopharma 179
Dongwha Pharm Enters into Licensing Agreement with Merck 180
Merck Enters into Licensing And Option Agreement with AIMM Therapeutics 181
Merck Enters into Licensing Agreement with Teijin Pharma 182
Kyorin Pharma Enters into Licensing Agreement with Merck 183
Urovant Sciences Enters into Licensing Agreement with Merck Sharp & Dohme 184
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 185
Ascentage Pharma Enters into Licensing Agreement with Merck 186
Merck Expands Licensing Agreement with Moderna Therapeutics 187
Merck Enters into Licensing Agreement with Harvard University 189
Merck Enters into Licensing Agreement with AureoGen Biosciences 190
Merck Enters into Licensing Agreement with Cancer Research Technology 191
Adimab Enters into Licensing Agreement with Merck 192
Merck Enters into Licensing Agreement with Selvita 193
Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 194
Allergan Enters into Licensing Agreement with Merck 196
Merck Extends Licensing Agreement with Agenus 197
Arvinas Enters into Licensing Agreement with Merck 198
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 199
Merck Enters into Licensing Agreement with BioNovion 200
Zymeworks Extends Licensing Agreement with Merck 201
Merck Enters into Licensing Agreement with NewLink Genetics 202
Euroscreen Enters into Licensing Agreement with Merck 204
Sun Pharma Enters into Licensing Agreement with Merck 205
Kyorin Pharma Enters into Licensing Agreement with Merck 206
Bionomics Enters into Licensing Agreement with Merck for BNC375 207
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 208
Gulf Pharma Enters into Licensing Agreement with MSD 209
Gulf Pharmaceutical Industries (Julphar) Enters into Licensing Agreement with Merck 210
NanoBio Enters Into Licensing Agreement With Merck 211
Merck Expands Licensing Agreement with Ablynx 212
ARMO Biosciences Enters into Licensing Agreement with Merck 214
Bionomics Extends Licensing Agreement with Merck 215
Xencor Enters Into Licensing Agreement With Merck 216
Cerecor Enters Into Licensing Agreement With Merck For MK-0657 217
Meiji Seika Pharma Enters into Licensing Agreement with MSD 218
Merck Enters into Licensing Agreement with Ra Pharma 219
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 221
Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 222
Menlo Therapeutics Enters into Licensing Agreement with Merck 223
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 224
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 225
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 226
MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 227
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 228
Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 229
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 230
Merck Enters into Licensing Agreement with Medicines Patent Pool 231
EnWave Enters into Licensing Agreement with Merck 232
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 233
Polyplus-transfection Enters Into Licensing Agreement With Merck 235
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 236
Merck Enters Into Licensing Agreement With Lupin 238
Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 239
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 240
Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 241
Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 242
Merck Enters Into Licensing Agreement With Yamasa For EFdA 243
Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 244
Merck Extends Licensing Agreement with Codexis 245
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 246
Bionomics Raises USD9 Million in Private Placement of Shares 247
OpGen Raises USD5 Million in Private Placement of Shares 248
BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 249
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 250
BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 251
Trius Therapeutics Completes Public Offering Of Shares For US$34 Million 252
Trius Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$5 Million 253
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 255
Trius Therapeutics Completes Over-allotment Option Of Underwritten Public Offering For US$52 Million 256
Merck Plans to Raise Funds through Public Offering of Debt Securities 258
Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 259
Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 260
Merck Completes Public Offering of Notes Due 2020 for USD700 Million 261
Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 263
Merck Completes Public Offering of Notes Due 2017 for USD300 Million 265
Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 267
Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 269
Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 271
Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 273
Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 275
Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 277
Cubist Pharma Completes Private Placement Of Notes Due 2020 For US$450 Million 279
Cubist Pharma Completes Private Placement Of Notes Due 2018 For US$350 Million 280
Merck Completes Public Offering Of Notes Due 2016 For US$500 Million 281
Merck Completes Public Offering Of Notes Due 2016 For US$1 Billion 283
Merck Completes Public Offering Of Notes Due 2018 For US$1 Billion 285
Merck Completes Public Offering Of Notes Due 2023 For US$1.75 Billion 287
Merck Completes Public Offering Of Notes Due 2043 For US$1.25 Billion 289
Merck Completes Public Offering Of Floating Notes Due 2018 For US$1 Billion 291
BeiGene Raises USD3 Million in Private Placement of Notes 293
Merck Completes Public Offering Of Notes Due 2042 For US$500 Million 294
Merck Completes Public Offering Of 1.1% Notes Due 2018 For US$1 Billion 296
Merck Completes Public Offering Of Notes Due 2022 For US$1 Billion 298
Pharmaron Acquires Hoddesdon UK Site from Merck Sharpe & Dohme 300
Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 301
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 303
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 304
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 305
Fareva Acquires La Vallee Manufacturing Site from Merck 306
Merial Acquires Manufacturing Facility from Merck 307
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 308
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 310
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 312
KBI Biopharma To Acquire Biologics Operations Of Merck 314
Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 315
Oak Pharma Acquires Tafluprost Business from Merck 316
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 317
Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme 318
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 319
Cerecor Acquires Rights To COMT Inhibitors From Merck 320
Kyorin Acquires Production Facility from MSD 322
Merck Acquires Viralytics for USD394 Million 323
Merck Acquires Rigontec 325
Paratek Pharma May Sell Itself 327
Merck Acquires Afferent Pharma 329
Merck Acquires IOmet Pharma 330
Merck Acquires cCAM Biotherapeutics 331
Merck Acquires Cubist Pharma for USD9.5 Billion 332
Merck Acquires OncoEthix for USD375 Million 334
Merck Completes Acquisition of Idenix Pharma for USD3.9 Billion in cash 335
Alnylam Pharma Acquires Sirna Therapeutics From Merck 337
Akorn Acquires Inspire Pharma From Merck For US$53 Million 338
Cubist Pharma Completes Acquisition of Optimer Pharma for up to USD801 Million 340
Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To US$818 Million In A Tender Offer 342
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 344
Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 346
Merck & Co Inc, Key Competitors 347
Merck & Co Inc, Key Employees 348
Merck & Co Inc, Subsidiaries 350
Merck & Co Inc, Joint Venture 372

List of Figures
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 18
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20
Merck & Co Inc, Medical Devices Deals, 2012 to YTD 2018 22

★調査レポート[Merck & Co Inc (MRK):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10059)販売に関する免責事項を必ずご確認ください。
★調査レポート[Merck & Co Inc (MRK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆